Table 3. Outcomes of allo-HCT in MF... | American Society of Hematology

Table 3.

Outcomes of allo-HCT in MF stratified by DIPSS

Lead author/ Reference	Disease and no. of patients	1-y outcomes	5-y outcomes	Impact of clinical risk score	Notes
Scott 2012²⁶	170 MF patients who underwent allo-HCT	OS = 74% RFS = 68% NRM = 26%	OS = 57% RFS = 57% NRM = 34%	HR for OM across risk scores: Low: 1 Int-1: 1.97 Int-2: 3.15* High: 4.11*	Single-center, JAKi-naive population
Kröger 2015²⁷	190 PMF patients who underwent allo-HCT 238 PMF patients who underwent non-tx strategies	OS for allo-HCT† Low = 100% Int-1 = 78% Int-2 = 82% High-risk = 65% OS for nontransplant† Low = 98% Int-1 = 97% Int-2 = 77% High = 67%	OS for allo-HCT† Low-risk = 69% Int-1 = 52% Int-2 = 50% High-risk = 32% OS for non-tx† Low = 95% Int-1 = 77% Int-2 = 41% High = 11%	RR of death after allo-HCT vs non-tx: Low = 5.6* Int-1 = 1.6 Int-2 = 0.55* High = 0.37*	2 multicenter databases, JAKi-naive population
Gowin 2020²⁸	551 MF patients who underwent allo-HCT 1337 MF patients who underwent non-tx strategies	Not reported	OS for allo-HCT† Low = 73% Int-1 = 73% Int-2/high = 44% OS for non-tx† Low = 82% Int-1 = 57% Int-2/High = 32%	HR of 1-y OM in non-tx vs allo-HCT: Low = 0.16* Int-1 = 0.26* Int-2/high = 0.39* HR of OM beyond 1 y in non-tx vs allo-HCT: Low = 1.38 Int-1 = 2.64* Int-2/high = 2.55*	Multicenter, both JAKi-naive and JAKi-treated patients Impact of allo-HCT vs non-tx on survival was consistent whether patients received ruxolitinib or not

Lead author/ Reference	Disease and no. of patients	1-y outcomes	5-y outcomes	Impact of clinical risk score	Notes
Scott 2012²⁶	170 MF patients who underwent allo-HCT	OS = 74% RFS = 68% NRM = 26%	OS = 57% RFS = 57% NRM = 34%	HR for OM across risk scores: Low: 1 Int-1: 1.97 Int-2: 3.15* High: 4.11*	Single-center, JAKi-naive population
Kröger 2015²⁷	190 PMF patients who underwent allo-HCT 238 PMF patients who underwent non-tx strategies	OS for allo-HCT† Low = 100% Int-1 = 78% Int-2 = 82% High-risk = 65% OS for nontransplant† Low = 98% Int-1 = 97% Int-2 = 77% High = 67%	OS for allo-HCT† Low-risk = 69% Int-1 = 52% Int-2 = 50% High-risk = 32% OS for non-tx† Low = 95% Int-1 = 77% Int-2 = 41% High = 11%	RR of death after allo-HCT vs non-tx: Low = 5.6* Int-1 = 1.6 Int-2 = 0.55* High = 0.37*	2 multicenter databases, JAKi-naive population
Gowin 2020²⁸	551 MF patients who underwent allo-HCT 1337 MF patients who underwent non-tx strategies	Not reported	OS for allo-HCT† Low = 73% Int-1 = 73% Int-2/high = 44% OS for non-tx† Low = 82% Int-1 = 57% Int-2/High = 32%	HR of 1-y OM in non-tx vs allo-HCT: Low = 0.16* Int-1 = 0.26* Int-2/high = 0.39* HR of OM beyond 1 y in non-tx vs allo-HCT: Low = 1.38 Int-1 = 2.64* Int-2/high = 2.55*	Multicenter, both JAKi-naive and JAKi-treated patients Impact of allo-HCT vs non-tx on survival was consistent whether patients received ruxolitinib or not

HR, hazard ratio; non-tx, nontransplant; JAKi, JAK inhibitor; NRM, nonrelapse mortality; OM, overall mortality; RFS, relapse-free survival; RR, relative risk. See Table 1 for expansion of other abbreviations.

Statistically significant.

†

Stratified by DIPSS.

View Large

This Feature Is Available To Subscribers Only